Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 11867311.
- Also identified by PMC identifier 1447080.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study evaluated the validity of concerns about the toxicity of nevirapine (NVP) that have delayed its implementation as a perinatal HIV prevention strategy. A decision analysis model compared 3 strategies: single-dose NVP, short-course zidovudine (ZDV), and no intervention. NVP would prevent more deaths than ZDV and no intervention as long as the rate of NVP toxicity did not exceed, respectively, 9 times that observed in the earlier NVP clinical trial and 42 times that observed in the clinical trial. NVP would be economically preferable to ZDV as long as the rate of toxicity did not exceed 22 times that observed in the clinical trial. Field implementation of NVP should not be delayed by concerns about its toxicity.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- Infectious Disease Transmission, Vertical
- Nevirapine
- Perinatal Care
- Zidovudine